Phase I/II Trial of IDEC-Y2B8 Radioimmunotherapy for Treatment of Relapsed or Refractory CD20<sup>+</sup>B-Cell Non-Hodgkin's Lymphoma - Concepedia

Concepedia

Publication | Closed Access

Phase I/II Trial of IDEC-Y2B8 Radioimmunotherapy for Treatment of Relapsed or Refractory CD20<sup>+</sup>B-Cell Non-Hodgkin's Lymphoma

538

Citations

25

References

1999

Year

Thomas E. Witzig, Christine A. White, Gregory A. Wiseman, Leo I. Gordon, Christos Emmanouilides, Andrew Raubitschek, Nalini Janakiraman, John Gutheil, Russell J. Schilder, Stewart Spies,

Journal of Clinical Oncology

Abstract

These phase I/II data demonstrate that IDEC-Y2B8 radioimmunotherapy is a safe and effective alternative for outpatient therapy of patients with relapsed or refractory NHL. A phase III study is ongoing.

References

	Year	Citations

Page 1